LAANTERN: Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System

Sponsor
Monteris Medical (Industry)
Overall Status
Recruiting
CT.gov ID
NCT02392078
Collaborator
(none)
3,000
29
242
103.4
0.4

Study Details

Study Description

Brief Summary

The NeuroBlate® System (NBS) is a minimally invasive robotic laser thermotherapy tool that is being manufactured by Monteris Medical. Since it received FDA clearance in May 2009, the NBS has been used in over 2600 procedures conducted at over 70 leading institutions across United States. This is a prospective, multi-center registry that will include data collection up to 5 years to evaluate safety, QoL, and procedural outcomes including local control failure rate, progression free survival, overall survival, and seizure freedom in up to 1,000 patients and up to 50 sites.

Condition or Disease Intervention/Treatment Phase
  • Device: NeuroBlate System

Study Design

Study Type:
Observational
Anticipated Enrollment :
3000 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN) Prospective Registry
Actual Study Start Date :
Oct 1, 2015
Anticipated Primary Completion Date :
Dec 1, 2030
Anticipated Study Completion Date :
Dec 1, 2035

Outcome Measures

Primary Outcome Measures

  1. Safety (Reportable adverse events) [up to 12 months]

    Safety profile described by the NBS and surgical-related AEs

  2. Reason for NeuroBlate [Index procedure]

    To identify the primary reason the NeuroBlate system was chosen for subject

  3. Number of patients demonstrating local control, overall survival, and seizure freedom (ENGEL and ILAE classifications) [up to 12 months or last follow-up]

    Collected for all subjects by disease etiology. Local control as measured by time to local tumor recurrence. Overall survival assessed by Kaplan-Meier method. Seizure freedom assessed for all subjects with epilepsy at time of last follow-up. The ENGEL surgical outcome scale is composed of four classes of epilepsy (Class I, Class II, Class III, Class IV) categorized by severity. The ILAE outcome scale contains six classes (Class 1, 2, 3, 4, 5, 6) categorized by severity.

  4. Change in Quality of Life [up to 12 months or last follow-up]

    Assessed by the following questionnaires: KPS (subjects with CNS malignancy): Scale ranged 0-100 measuring the ability of patients with cancer to perform ordinary daily activities FACT-Br (subjects with CNS malignancy): Measures general quality of life reflecting symptoms associated with brain malignancies across 5 scales (physical well-being social/family well-being, emotional well-being, functional well-being, and other) EQ-5D (all subjects): A generic measure of health consisting of the descriptive system and the visual analogue scale (VAS). The descriptive system assesses subject mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The VAS reports the subject's self-rated health QOLIE-31 (subjects with epilepsy): Contains 7 scales assessing emotional well-being, social functioning, energy/fatigue, cognitive functioning, seizure worry, medication effects, and overall quality of life for adults

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Subject or legally authorized representative provides written authorization and/or consent

  2. Subject who is to undergo thermal therapy by the NeuroBlate® System for treatment of their neurological disorder

Exclusion Criteria:
  1. Subject who is, or is expected to be inaccessible for follow-up

  2. Other concurrent medical or other condition (chronic or acute in nature) that in the opinion of the investigator, may prevent participation or otherwise render subject ineligibility for the study

Contacts and Locations

Locations

Site City State Country Postal Code
1 Barrow Neurological Institute at Dignity Health St. Joseph's Hospital & Medical Center Phoenix Arizona United States 85013
2 University of Arkansas for Medical Sciences Little Rock Arkansas United States 72205
3 University of California, San Diego La Jolla California United States 92093
4 Children's Hospital of Orange County Orange California United States 92868
5 Yale University School of Medicine New Haven Connecticut United States 06510
6 Advent Health Orlando Orlando Florida United States 32804
7 The Cleveland Clinic Florida Weston Florida United States 33331
8 Northwestern University Chicago Illinois United States 60611
9 University of Kansas Medical Center Kansas City Kansas United States 66160
10 University of Louisville Louisville Kentucky United States 40208
11 Norton Cancer Institute Louisville Kentucky United States 40241
12 University of Minnesota Minneapolis Minnesota United States 55455
13 United Children's Hospital St. Paul Saint Paul Minnesota United States 55102
14 Washington University Saint Louis Missouri United States 63110
15 New York University Langone Medical Center New York New York United States 10016
16 Icahn School of Medicine at Mount Sinai New York New York United States 10029
17 Weill Cornell Medicine New York New York United States 10065
18 SUNY Upstate Medical University Syracuse New York United States 13210
19 Duke University Medical Center Durham North Carolina United States 27710
20 Wake Forest Winston-Salem North Carolina United States 27157
21 University Hospitals Cleveland Medical Center Cleveland Ohio United States 44106
22 Cleveland Clinic Foundation Cleveland Ohio United States 44195
23 Geisinger Medical Center Danville Pennsylvania United States 17822
24 Thomas Jefferson University Philadelphia Pennsylvania United States 19107
25 University of Pittsburgh Medical Center Pittsburgh Pennsylvania United States 15213
26 Saint Thomas West Hospital and Research Institute Nashville Tennessee United States 37205
27 University of Texas Southwestern Medical Center Dallas Texas United States 75390
28 MD Anderson Houston Texas United States 77030
29 University of British Columbia Vancouver British Columbia Canada V5Z 1M9

Sponsors and Collaborators

  • Monteris Medical

Investigators

  • Principal Investigator: Eric Leuthardt, MD, Washington University School of Medicine

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Monteris Medical
ClinicalTrials.gov Identifier:
NCT02392078
Other Study ID Numbers:
  • LAANTERN
First Posted:
Mar 18, 2015
Last Update Posted:
Aug 23, 2022
Last Verified:
Jul 1, 2021

Study Results

No Results Posted as of Aug 23, 2022